Since drug resistance mutations in HIV-1 have been increasingly reported to resist most of the current drug repertoire in the antiretroviral therapy, there is a demand for new drugs. In this study, we focused on the viral enzyme Reverse Transcriptase (RT) as it is a good drug target given its absence in non-viruses. Through a reverse transcription assay screen, we found two out of forty compounds from the NCI Diversity Set V to inhibit HIV-1 RT activity. The less potent compound also inhibited MMLV RT. Molecular docking, structural conservation and binding pocket analyses suggested similar binding mechanisms of the dual inhibitor to the targets, implying that the phenylbenzoic scaffold may be potentially used to design broad-spectrum inhibitors against multiple Reverse Transcriptase enzymes from multiple viruses.
INTRODUCTION
Human Immunodeficiency Virus (HIV) infection remains one of the major global epidemics today with millions infected 1 . The current cocktail antiretroviral therapy (ART) targets various stages of the viral life cycle, such as using Protease Inhibitors (PIs to interfere Protease binding to its substrate Gag during viral maturation 2 ); Reverse Transcriptase Inhibitors (RTIs to inhibit viral DNA production 3 ); Integrase Inhibitors (to block viral DNA insertion into the host genome 4 ); and many others that include chemokine receptor antagonists 5 , attachment inhibitors 6 , and pharmacokinetic enhancers 7 .
While PI is the most used drug class in ART due to lower rates of induced drug resistance, it is a significant challenge in terms of treatment cost despite being the recommended first line of treatment by WHO 8 . On the other hand, the RTI drug class (including nucleoside (NRTI) and non-nucleoside (NNRTI) inhibitors) within ART is more affordable, and is safer since it targets RT that is unique to viruses, making it more suitable than PIs for a subset of the treatment population (e.g. children, pregnant women, or individuals treated tuberculosis with rifampicin).
The two RTI categories: NRTIs and NNRTIs inhibit RT function by different mechanisms.
NRTIs bind to the nucleotide binding site and block the reverse transcription by competing with dNTPs 9 , terminating the DNA elongation process 10 and thereby viral replication. In contrast, NNRTIs bind to a pocket located near the polymerase active site, and change the structural alignment of the dNTPs and template/primer substrates at the RT "primer grip", thus inducing distal effects on the polymerase active site 11 , consequently inhibiting reverse transcription 12 . Unlike NRTIs, which are known to interfere with cellular replication machinery 13 , NNRTIs vary in structure, generally do not exhibit off-target effects, and have been found to non-competitively allosterically cause conformational changes in the RT structure 14 . To resist NNRTIs, HIV mutates at the drug-binding pocket 15 that is less conserved.
In the battle against viral drug resistance, broad spectrum antivirals with high barrier to resistance have been proposed as an alternative solution to inhibit multiple virus families as they bind to binding sites with common features and conserved structural sites [16] [17] [18] . For example, broad spectrum antiviral inhibitors [19] [20] [21] that block multiple viral families protease activity (such as Xenotropic murine leukemia virus-related virus, Human T-lymphotropic virus, and Feline immunodeficiency viruses) were also blocked HIV-1 protease. In the case of RT, although several RT broad spectrum inhibitors were found against various HIV-1 strains [22] [23] [24] , there have been so far none against across multiple retrovirus families. Thereby, targeting conserved regions across all viral RT may also be effective within drug resistant variants.
HIV-1 RT is a heteromeric complex, made up of the p66 and p51 subunits. The larger p66 subunit contains five subdomains: fingers, palm, thumb, connection and RNaseH subdomains. Despite having an identical sequence to that of p66 excluding the RNaseH subdomains, the p51 subunit forms a more compact structure 25 . To date, no inhibitors that target the p51 subunit are used in the clinics.
Given that WHO guidelines recommends the use of NNRTIs, a guide to NNRTI drug selection usage and novel allosteric druggable sites in HIV-1 RT 26 was proposed previously which may alleviate drug resistance. Furthering this, we experimentally screened a diverse set of chemical compounds using the RT-PCR assay. In addition to computational molecular docking, structural conservation and inhibitor-binding pocket analyses, we further studied the mechanisms of how the inhibitors bound to the RT structures, finding a possible scaffold for broad spectrum RT inhibitor design that may be effective across mutant variants of HIV-1 RT and that of other viruses.
RESULTS

Two novel compounds that could inhibit RT activity
GAPDH housekeeping gene PCR was used as cDNA synthesis target given its high and consistent expression 27 . Preliminary RT-PCR screening of 40 compounds from the NCI/DTP Diversity Set V at 300 µM showed that two compounds, i.e. NSC48443 and NSC127133 (thereafter named compound 1 and 2, respectively) inhibited HIV-1 RT cDNA synthesis ( Figure 1 ). The inhibition did not occur during the GAPDH PCR step (Supplementary Figure   S1A ) given that bands were still observed when the inhibitors were only added after the cDNA synthesis. A non-inhibitor from the preliminary RT-PCR screen (NSC6145) was randomly picked as a negative control for the experiments. Compounds 1 and 2 were found to partially inhibit HIV-1 RT in independent triplicates at 150 and 300 µM respectively ( Figure 1 ) and PCR products were observed to decrease at higher concentrations. 
Broad-spectrum RT inhibitors
In order to determine if the two compounds could function as broad-spectrum RT inhibitors, we performed similar RT-PCR functional assays on another RT enzyme (i.e. Moloney Murine Leukemia Virus (MMLV) RT available in our lab). Among the two compounds, only compound 2 was found to inhibit the MMLV RT activity at concentrations above 400 µM We next performed computational blind dockings using the Achilles Blind Docking Server 28, 29 . The dockings were individually performed using compound 2 structure (as ligand) to both the RT structures (as receptors) without specifying the binding regions. It was shown that compound 2 bound to several regions in HIV-1 RT, mostly on the p51 domain, as well as specific regions in MMLV RT ( Figure 3A ). Among the binding sites on both HIV-1 and MMLV RT, we found that one particular site shared structural similarity between HIV-1 p51 domain and MMLV RT where compound 2 conformers were highly populated (~11.17% and ~9.22%, respectively, of the total conformer sampling). Docking affinity scores of the compound 2 conformers to the HIV-1 RT p51 and MMLV RT binding sites were also found among the top highly ranked results in both HIV-1 (rank 2) and MMLV (rank 7)
( Supplementary Table S5 ). 32 ).
In addition, we found that the common binding site on both HIV-1 and MMLV RT were conserved among the RT protein family (Figure 3B, Supplementary Figure S2 and S3 ). It was also shown that compound 2 has a phenylbenzoic acid group that was likely to be involved in these bindings to both the regions that contain a predominantly charged region adjacent to a hydrophobic patch in both the HIV-1 p51 and MMLV RT (Supplementary Figure S4 ). This phenylbenzoic acid group might be crucial to the binding of compound 2 (but absent in the 39 other compounds tested) to both the RT regions.
DISCUSSION
We set out to search for novel HIV-1 NNRTI alternatives by experimentally screening 40 compounds of the NCI Diversity Set V. We identified two compounds that could inhibit the HIV-1 RT activity, and of the two compounds, the less potent compound 2 also inhibited MMLV RT function.
Computational structural analyses suggested a common binding site for compound 2 on both the RT structures that was conserved among the RT protein families as well as across viruses infecting different species, thereby suggesting the scaffolds for novel broad-spectrum RT inhibitor design. Both the binding regions in HIV-1 p51 and MMLV RT were found to be conserved among the RT families and they shared similar binding mechanism with compound 2 conformers, particularly via the phenylbenzoic acid group. Therefore, the phenylbenzoic acid group could be used as a scaffold template for the design of potent inhibitors against retroviral RT. Furthermore, our structural conservation analysis revealed that the common binding region on MMLV RT and HIV-1 p51 was also present across multiple Reverse Transcriptases (Supplementary Data 1) .
In addition to p51 domain binding, compound 2 was also found to interact with p66 (at lower frequency, Figure 3A ) away from the polymerase site in our blind docking analysis, suggesting the involvement of allostery. Since the structural folds of p51 differed from that of p66 subunits (e.g. overall RMSD ~4.93 Å, excluding the RNase H region) but shared similar structural characteristics on MMLV RT, it was likely that the main inhibition site by the compound 2 was located on p51 of HIV-1 RT.
Studies 33, 34 showed that p66 or p51 homodimers of HIV-1 RT remained functional, albeit at reduced activity. Thus, it is likely that compound 2 might also be able to inhibit the p66 homodimer formation/activity. In our assay, we did not find the PCR reactions with the p51 alone to produce detectable bands after PCR, even in the negative control (Supplementary Figure S1B ). However, faint bands were detected for the p66 alone in the case of compound 2 (and also of the negative control), but there was none in the case of compound 1 (Supplementary Figure S1B) . Such a result strongly supports the computational analysis that compound 2 was unlikely to bind to p66 but instead displayed its effect by binding to p51, whereas the inhibition of compound 1 was likely to be narrowed to p66 subunit. From this observation, the predominant inhibition of compound 2 on p51 may explain why compound 2 was only able to inhibit at much higher concentrations than compound 1 ( Figure 1A) . Given that the active site of RT is located on p66 for the HIV-1, the inhibition likely involves an allosteric mechanism.
With possible inhibition via the phenylbenzoic acid group on HIV-1 RT, there is great promise to further modify and design broad-spectrum RTIs, and possible safer ones with lower toxicity against multiple viral RTs and mutant HIV-1 RTs. The conservation of the site suggests its crucial role across viruses, thus making it an attractive target for drug-resistant HIV-1 RT variants. Just as viruses can develop cross-resistance to multiple drugs 26, 35 , it is possible to have cross-inhibition against multiple viral RT. With the potential of allosteric inhibitors, rational drug design can be more diverse beyond the scaffold of nucleosides in NRTIs and be targeted against specific RTs at different levels while maintaining the broadspectrum activity. To do this, it would be necessary to take a holistic approach 36 in studying the whole structure of the target proteins. Such an approach has been shown to be important in the studies of HIV-1 Gag 37 , HIV-1 Protease 35 , and antibodies [38] [39] [40] [41] [42] , in the search for allosterically important regions that if conserved, would be likely broad-spectrum druggable targets.
In conclusion, we found two potential inhibitors from our experimental screen that inhibited HIV-1 RT. One of the inhibitors demonstrated cross-inhibition to MMLV RT at a similar conserved binding site across viral RTs, and likely inhibited HIV-1 RT via its binding to the p51 subunit, against which no known clinical drugs target. We propose that this compound could serve as a scaffold for inhibitor design as a broad-spectrum RTI, and certainly in the case of HIV-1, one of the first p51 targeting inhibitors.
METHODS
RNA Extraction
RNA was extracted from overnight cultured EXPI293F (Invitrogen, Cat no. A14527) cells using TRIzol Reagent (ThermoFisher Scientific, Cat. No.: 15596018) according to the manufacturer's recommendations. The RNA was treated with RNase-free DNase I (Roche, Cat. No.: 04716728001) and stored at -80 °C. 
Library Reagent Preparation
cDNA synthesis Reverse Transcription (HIV-1 & MMLV)
All the library compounds were first heated to 37 °C for 10 min for better solubility prior to addition into RT reaction mix. min. Agarose Gel Electrophoresis was carried out on the PCR products using a 2% agar gel and GAPDH amplified products were analysed and confirmed using GelApp 43 .
Structural Analysis & Blind Docking
The chemical structure of compound 2 (NSC127133 from the Diversity Set V) was retrieved from the National Cancer Institute Developmental Therapeutic Program (NCI/DTP). The 2D
structures were then converted into 3D structures using Open Babel 44 . Wild type HIV-1 RT structure (PDB: 3T19, preprocessed as previously 26 ) and MMLV RT structure (PDB: 5DMQ) were used.
Missing residues were first added into the MMLV RT using Modeller 45 and Swiss-Pdb Viewer 46 and followed by energy minimization using UCSF Chimera 47 . The blind docking calculations were performed using HIV-1 RT and MMLV RT structures as receptors and the converted compound 2 structure as ligand using Achilles Blind Docking Server 28, 29 (available at http://bio-hpc.eu/software/blind-docking-server/), which have demonstrated successful prediction of binding poses in various academic studies 48, 49 and industrial projects 28 . We selected the binding regions on the receptors with the most populated ligand boundconformers for analysis. To minimize possible confounding factors (e.g. disrupting the HIV-1 RT structural stability by interfering the interactions between p66 and p51 domains), we excluded the binding regions at the HIV-1 RT p66/p51 interface.
Analysis of structural conservation among RT proteins
Multiple sequence alignment of the HIV-1 and MMLV RT sequences with 152 retrovirus RT sequences (retrieved from NCBI RefSeq Databases) was first performed using ClustalW 50 .
The resulting alignment was then subjected to the ConSurf server 30, 31 with default parameters to study the conservation of the regions of interest across the RT families.
